Derivatives of Schiff bases have been considerably screened for their anticancer potential. We aimed to investigate in-vitro anticancer activity of two transition metal compounds of derived Schiff bases; NM-3 (Tetrakis (2-{(E)-[(2- {[(Z)-(2-hydroxynapthyl) methylidene] amino} phenyl) imino] methyl} phenol) Copper(II) and NM-4 (Tetrakis (2-{(E)-[(2-{[(Z)-(2-hydroxynapthyl) methylidene] amino} phenyl) imino] methyl} phenol) zinc(II)), against human THP-1 leukemia cell line in-relation to miltefosine (standard chemotherapy). Mean % inhibition for NM-3 against THP-1 was higher than NM-4, although both were less effective than miltefosine. IC50 for miltefosine, NM-3 and NM-4 against THP-1 was 0.000347 mu M, 44.9 mu M and 119 mu M; whereas, their cytotoxicity was 72.26 mu M, 255 mu M and 293.8 mu M, respectively against peripheral blood lymphocytes. Based on the findings of present study the compounds can be put in to list of candidacy for anticancer activity.